22.06 USD
▲+1.36+5.85%
盘后 20.84 0.00%
2026-08-03
市值
$416.15M
市盈率
—
EPS
-14.64
股息率
—
52 周区间
17.31 – 25.49
成交量
149.96K
Beta
—
目标价
—
52W 低 17.3152W 高 25.49
价格走势
公司简介
Scribe Therapeutics Inc. operates as a clinical-stage biotechnology company, focuses on research and developing genetic medicines using CRISPR-based tools to address the root cause of diseases, with a primary focus on cardiometabolic conditions in the United States. The company offers STX-1150 designed to be a single-course in vivo epigenetic silencing treatment targeting the PCSK9 gene; STX-1200 is CRISPR-based gene editing program that aims to offer a permanent solution for patients with elevated Lp(a); and STX-1400 is designed to target and ...